ScoreWhy is Egetis Therapeutics AB ?
1
Poor long term growth as Net Sales has grown by an annual rate of 0.96% and Operating profit at -190.81% over the last 5 years
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 58.33%, its profits have fallen by -4.8%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Egetis Therapeutics AB for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Egetis Therapeutics AB
58.33%
-0.60
62.85%
OMX Stockholm 30
10.97%
0.59
18.59%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
0.96%
EBIT Growth (5y)
-190.81%
EBIT to Interest (avg)
-68.47
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.40
Sales to Capital Employed (avg)
0.10
Tax Ratio
0.12%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.99
EV to EBIT
-6.11
EV to EBITDA
-6.11
EV to Capital Employed
8.31
EV to Sales
42.48
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-136.00%
ROE (Latest)
-94.82%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend8What is working for the Company
NET PROFIT(HY)
Higher at SEK -155.8 MM
NET SALES(Q)
Highest at SEK 17.4 MM
OPERATING PROFIT MARGIN(Q)
Highest at -447.13 %
-6What is not working for the Company
ROCE(HY)
Lowest at -111.88%
INTEREST(Q)
At SEK 4.1 MM has Grown at 32.26%
RAW MATERIAL COST(Y)
Grown by 67.96% (YoY
DEBTORS TURNOVER RATIO(HY)
Lowest at 1.54 times
Here's what is working for Egetis Therapeutics AB
Net Sales
Highest at SEK 17.4 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (SEK MM)
Net Sales
At SEK 17.4 MM has Grown at 46.84%
over average net sales of the previous four periods of SEK 11.85 MMMOJO Watch
Near term sales trend is very positive
Net Sales (SEK MM)
Net Profit
Higher at SEK -155.8 MM
than preceding 12 month period ended Sep 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (SEK MM)
Operating Profit Margin
Highest at -447.13 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Here's what is not working for Egetis Therapeutics AB
Interest
At SEK 4.1 MM has Grown at 32.26%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (SEK MM)
Debtors Turnover Ratio
Lowest at 1.54 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
Raw Material Cost
Grown by 67.96% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
